(lp0
S'Epizyme Earns $6 Million Milestone Payment from GlaxoSmithKline for Initiation ... GlobeNewswire  - Sep 15, 2016 CAMBRIDGE, Mass., Sept. 15, 2016  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced it has earned a $6 million milestone payment from&nbsp;...'
p1
aS'Epizyme Inc.  Breaks into New 52-Week High on March 21 Session Equities.com - Mar 21, 2017 Shares of Epizyme Inc.  broke into a new 52-week high yesterday, hitting a peak of $17.75. Shares closed at $16.60 after opening at $17.25 for a move of -3.49%.'
p2
aS"Option Market Alert: Epizyme Inc Implied Price Swing Hits An Escalated Level CML News - Mar 20, 2017 Risk Alert: Before we dive into any analysis we simply note that Epizyme Inc  risk is elevated. We'll detail it below -- but that's the lede -- the option market is starting to flash those neon lights that signal &quot;risk is rising&quot; with an ..."
p3
aS'Epizyme Elects Kevin Conroy to its Board of Directors GlobeNewswire  - Feb 7, 2017 CAMBRIDGE, Mass., Feb. 07, 2017  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company has elected industry veteran Kevin Conroy,&nbsp;...'
p4
aS'Analyst Observation On 2 Stocks: Epizyme, Inc. , MAXIMUS, Inc.  Post Analyst - 12 hours ago The earnings of MAXIMUS, Inc.  are forecasted by the analysts to move at $0.77 in current quarter, from $0.74 a year-ago quarter.'
p5
aS'Epizyme Announces Presentation at JP Morgan 35th Annual Healthcare Conference GlobeNewswire  - Jan 3, 2017 CAMBRIDGE, Mass., Jan. 03, 2017  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that Robert Bazemore, chief executive officer of Epizyme, will&nbsp;...'
p6
aS'Epizyme Inc.  Breaks into New 52-Week High on March 16 Session Equities.com - Mar 16, 2017 Shares of Epizyme Inc.  broke into a new 52-week high yesterday, hitting a peak of $17.45. Shares closed at $16.95 after opening at $16.95 for a move of 0%.'
p7
aS'Epizyme President of Research and Chief Scientific Officer, Robert Copeland ... GlobeNewswire  - Mar 9, 2017 CAMBRIDGE, Mass., March 09, 2017  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of Research and Chief Scientific Officer, Robert&nbsp;...Epizyme  Reports A Narrower Q4 Loss - Yahoo FinanceEPIZYME, INC.  Files An 8-K Results of Operations and Financial ... - Market Exclusive'
p8
aS'Epizyme Establishes Collaboration with Foundation Medicine to Support ... GlobeNewswire  - Sep 21, 2016 CAMBRIDGE, Mass., Sept. 21, 2016  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced that the Company has entered into a collaboration agreement&nbsp;...'
p9
aS'Stock Volatility Risk Alert: Epizyme Inc Stock Volatility Hits An Unsually ... CML News - Mar 19, 2017 Before we cover the full analysis we make a quick alert here that Epizyme Inc  has seen its stock price whip around at an unsually high level.'
p10
a.